Document:

EX-10.2

 Exhibit 10.2 
  

 
 March 2, 2015 
 Dan
Menichella 
 1555 Queens Road West 
 Charlotte, NC 28207 

Dear Dan: 
 This letter agreement
(“Agreement”) will confirm the terms of your separation from employment with Applied Genetic Technologies Corporation (“AGTC” or the “Company”), a Florida company. This Agreement will become effective on the eighth day
following your execution of it, as described in section 7 below (the “Effective Date”). 
 1. Separation of
Employment. Your employment with the Company has terminated, without cause, effective January 28, 2015 (the “Separation Date”). You understand and acknowledge that, from and after the Separation Date, you shall have no
authority and shall not represent yourself as an employee or agent of the Company or any of its affiliates. Notwithstanding the foregoing, you agree that you will cooperate with the Company’s reasonable requests for information and assistance
in connection with the transitioning of your duties. 
 2. Pay Continuation. Contingent on your execution of this Agreement
and it becoming effective as described in section 7, the Company will pay you an amount equal to six (6) months of your current base salary ($290,000.00 annualized), less all required local, state, federal and other employment-related taxes and
deductions (the “Severance”). The Severance will be paid in one lump sum, in a check in the amount of $145,000 upon execution of this Agreement, in accordance with the company’s standard payroll policies. 

3. Pay and Benefits Acknowledgement. You acknowledge that on the Separation Date, you were paid your salary for time worked
through the Separation Date, two weeks’ pay provided in lieu of notice of termination, as well as the value of your accrued and unused PTO. You also will be reimbursed for outstanding expenses in accordance with the Company’s expense
reimbursement policy. You acknowledge and understand that, except for the specific financial consideration and other benefits contained in this Agreement, you are not entitled to and shall not receive any additional compensation, consideration or
benefits from the Company. 
 4. Option. Pursuant to the Company’s 2013 Equity and Incentive Plan, the Company has issued
you options to purchase shares of the Company’s common stock (the “Option Shares”) as described in the letter attached hereto as Exhibit A. All further vesting of the Option shall cease as of the Separation Date, except that the
Options that were scheduled to vest for from the Separation Date until April 28, 2015 will vest upon execution of this Agreement. Your vested Option Shares are described in the letter attached to this Agreement as Exhibit A. After the
Separation Date, you will not be able to exercise the Option to purchase any Option Shares that are not vested Option Shares. After the Separation Date, you may exercise the Option in accordance with its terms to purchase some or all of the Vested
Shares until the date (the “Option Termination Date”) that is twelve months after the Separation Date (January 28, 2015). On or after the Option Termination Date, the Option will have terminated in accordance with its terms, and you will
no longer be able to exercise the Option to purchase any Option Shares. You acknowledge and understand that amending your option to provide for an additional period of time to exercise following the Separation Date will cause your option to no
longer qualify as an Incentive Stock Option, that it will automatically become a Non-statutory Stock Option, and that upon exercise, any spread between the exercise price and the fair market value of the Company’s common stock at that time will
become taxable at ordinary income rates. 

  
 

 

	5.	Covenants by You. You acknowledge and agree to the following: 

(a) You will return all property of the Company, including, without limitation, all computer hardware, software, mobile
phone(s), company credit cards, calling cards and any contracts or proposals, Company, documentation, files and other materials relating to the Company, whether in hard copy or electronic (or other) form, on or before February 11, 2015, unless
extended at the Company’s discretion. 
 (b) You continue to be bound by the terms of the Confidentiality, Inventions
and Non-Competition Agreement between you and the Company, which terms are in full force and effect and will survive the termination of your employment with the Company, except that Section 4 of the Confidentiality, Inventions and
Non-competition Agreement is superseded by the terms in this Agreement. To that end, Menichella and Company agree for a period of six months, starting on January 28, 2015 and ending on July 24, 2015, that Menichella will not directly be
involved with any of the following businesses or individuals: 
  

	 	*	Avalanche 

  

	 	*	Spark 

  

	 	*	ReGenx Bio 

  

	 	*	RetroSense 

  

	 	*	NightstarX 

  

	 	*	OxfordBiomedica 

  

	 	*	John Guy 

  

	 	*	Uniqure 

  

	 	*	Gensight 

 For purposes of this Agreement, “directly involved” means
being an employee, officer, director, or owning more than ten percent (10%) of one of the entities listed above. 
 (c) You will not
make any statements, whether orally or in writing (including in electronic communications) that are professionally or personally disparaging about the Company or its officers, directors, managers, employees or consultants 

(d) You agree that upon request to cooperate with and provide reasonable assistance to the Company and its legal counsel in connection with any
litigation (including without limitation arbitration or administrative hearings) or investigations affecting the Company, in which your assistance or cooperation is needed as determined by the Company or its legal counsel. You further agree that, in
the event you are subpoenaed by any person or entity (including without limitation any government agency) to give testimony which in any way relates to your employment by the Company or with respect to any relationship with the Company, you will
give prompt notice of such request to the Company and will not make any disclosure until the Company has had a reasonable opportunity to contest the right of the requesting person or entity to such disclosure. 

(e) You understand that if you breach any of these covenants, such breach shall constitute a material breach of this Agreement, and shall
relieve the Company of any further obligations to you under this Agreement. Furthermore, if you breach any of these covenants, you shall be required to reimburse the Company the amount of your continuation pay and the cost of any other benefits
provided to you by virtue of this Agreement, in addition to any other legal or equitable remedy available to the Company for such breach. 

6. Covenants by Company. The Company agrees that it will not make any statements, whether orally or in writing (including in electronic
communications) that are professionally or personally disparaging about Dan Menichella, his agents, future ventures, or future employers. If Company is asked about the separation, termination, or Menichella’s employment, they will respond:
“Mr. Menichella made important contributions to broadening awareness of AGTC’s programs, advancing important collaborations and securing valuable intellectual property rights for AGTC. He chose to pursue other ventures, and we wish him
well.” The only exception is if Mr. Menichella requests and obtains a specific letter of reference or recommendation from a particular person at Company, only at the request of Menichella. 

  
 

 

 7. Release of Claims. 

(i) You hereby agree and acknowledge that by signing this Agreement and accepting the pay, benefits and other consideration discussed above,
you are waiving your right to assert any and all forms of legal Claims against the Company1 of any kind whatsoever, arising from the beginning of time through the date you execute this Agreement.
With the sole and limited exceptions set forth in paragraph (ii) below, for purposes of this Section 6 the words “Claim” and “Claims” are intended to be as broad as the law allows and to mean: any and all charges,
complaints and other form of action against the Company, seeking any form of relief including, without limitation, equitable relief (whether declaratory, injunctive or otherwise), the recovery of any damages, or any other form of monetary recovery
whatsoever (including, without limitation, back pay, front pay, compensatory damages, equity (including stock or stock options), emotional distress damages, punitive damages, attorneys’ fees and any other costs) against the Company, including,
without limitation: 
 (a) Claims under any Florida, North Carolina (or any other state) or federal discrimination, fair employment practices
or other employment related statute, regulation or executive order (as they may have been amended through the date you sign this Agreement), including but not limited to Chapter 760 of the Florida Statutes and the federal Age Discrimination
Employment Act; 
 (b) Claims under any other Florida, North Carolina (or any other state) or federal employment related statute, regulation
or executive order (as they may have been amended through the date you sign this Agreement), including the Chapters 447 and 448 and Section 440.205 of the Florida Statutes; 

(c) Claims under any Florida, North Carolina (or any other state) or federal common law theory; and 

(d) Any other Claims arising under other state or federal law. 

(ii) Notwithstanding the foregoing, this Section 7 shall not release the Company from any obligation expressly set forth in this
Agreement, and does not preclude you from filing a charge of discrimination with the United States Equal Employment Opportunity Commission (“EEOC”), but you will not be entitled to any monetary or other relief from the EEOC or from any
Court as a result of litigation brought on the basis of or in connection with such charge. 
 (iii) You expressly acknowledge and agree that,
but for providing the foregoing release of Claims, you would not be receiving the pay and benefits being provided to you under the terms of this Agreement. 

8. Understanding this Agreement. Before signing this Agreement, you should take whatever steps you believe are necessary to
ensure that you understand what you are signing, what benefits you are receiving and what rights you are giving up. 
 (a) By signing this
Agreement, you are acknowledging that you have read it carefully and understand all of its terms. 
 (b) You understand and acknowledge that,
if you do not sign this Agreement, including the Release of Claims, you would not be receiving the Severance described in section 2. 
 (c)
You understand that, among other claims you are releasing in the Release of Claims are any claims against the Company alleging discrimination on the basis of age and claims for wages and/or overtime pay under Florida law. 

(d) You are hereby advised and encouraged to consult with legal counsel for the purpose of reviewing the terms of this Agreement. 

(e) You are being given twenty-one (21) days in which to consider this Agreement and whether to accept this Agreement. If you choose to
accept this Agreement within that time, you are to sign and date below and return it to the Company, care of Sue Washer, 11801 Research Drive, Suite D, Alachua, FL 32615. 

 

	1 	For purposes of this Section, the term “Company” includes Applied Genetic Technologies Corporation and any of its divisions, affiliates (which means all persons and entities directly or indirectly controlling,
controlled by or under common control with AGTC), parents, subsidiaries and all other related entities, and its and their directors, officers, employees, trustees, agents, successors and assigns. 

  
 

 

 (f) Even after executing this Agreement, you have seven (7) days after signing to revoke
this Agreement. The Agreement will not be effective or enforceable until this seven (7) day period has expired. In order to revoke your assent to this Agreement, you must, within seven (7) days after you sign this Agreement, deliver a
written notice of rescission to Sue Washer at the address noted above. To be effective, the notice of rescission must be hand delivered, or postmarked within the seven (7) day period and sent by certified mail, return receipt requested, to the
referenced address. 
 9. Entire Agreement. You understand and agree that this Agreement constitutes the full extent of the
Company’s commitment to you. You further understand and agree that this Agreement supersedes any prior agreements between you and the Company, except to the extent other agreements are specifically referenced herein and incorporated into this
Agreement. No changes to this Agreement will be valid unless reduced to writing and signed by you and the Company. 
 10. Choice of
Law/Enforceability. Agreement is made and entered into in the State of Florida and shall be governed by and construed in accordance with the laws of the State of Florida, except with regard to the conflict of laws rules of such State. 

11. General. By executing this Agreement, you are acknowledging that you have been afforded sufficient time to understand its
terms and effects, that your agreements and obligations under this Agreement are made voluntarily, knowingly and without duress, and that neither the Company nor its agents or representatives have made any representations inconsistent with the
provisions of this Agreement. 

  
 

 

 Your signature below reflects your understanding of, and agreement to, the terms and conditions
set forth above. 
  

			
	Very truly yours,
	
	Applied Genetic Technologies Corporation
		
	By:		 /s/ Susan B. Washer

  

			
	Confirmed and Agreed:
		
	 /s/ Dan Menichella
		
	 Dan Menichella
		

			
		
	Dated:		 3/3/2015

			

  
 

 

 Exhibit A 

March 2, 2015 
 Dan Menichella 

1555 Queens Road West 
 Charlotte, NC 28207 

Dear Dan: 
 I wanted to provide you a current list of your total
options, the price, the vested balance as well as expiration dates. If you have any questions regarding your options, please let me know. 
 For details,
see below: 
 Option detail for Daniel Menichella, vested through 04/28/2015: 
  

																													
	 Date of Grant
	  	Price	 	  	Granted	 	  	Terminated	 	 	Exercised	 	 	Options
Vested	 	  	Cost to Exercise
Vested Options	 	  	Total	 
	 09/18/13
	  	$	4.900	  	  	 	126,968	  	  	 	(76,710	) 	 	 	(18,000	) 	 	 	32,258	  	  	$	158,064.20	  	  			
	 04/17/14
	  	$	14.080	  	  	 	7,567	  	  	 	(5,676	) 	 	 	—  	  	 	 	1,891	  	  	$	26,625.28	  	  	$	184,689.48	  

 Please note that each Option shall terminate twelve (12) months following your termination date of January 28, 2015,
i.e. January 28, 2016. 
 Further, please note that as a result of the extension of the exercise period & vesting acceleration, the options
are no longer considered ISOs, rather all non-qualified. 
 If you have any questions regarding your options, please let me know. 

Sincerely, 
  

	
	 /s/ Susan B. Washer

	 Susan B. Washer

	 President & Chief Executive Officer

	 AGTCExhibit 10.1 Summary Compensation 03.31.2015 Q3 10Q

Exhibit 10.1
SUMMARY OF DIRECTOR AND NAMED EXECUTIVE OFFICER COMPENSATION
This summary sets forth the compensation of the Directors of Kimball Electronics, Inc. (the “Company”).  The summary also includes compensation of the Company’s current Chief Executive Officer, Chief Financial Officer, and the three other most highly compensated executive officers, who will be referred to herein as our “Named Executive Officers.”
For a detailed description of the compensation arrangements that the Directors and Named Executive Officers participate in, refer to the Company’s registration statement on Form 10, which the Securities and Exchange Commission declared effective on October 7, 2014 (“Form 10”).  The Company was a wholly owned subsidiary of Kimball International, Inc. (“former Parent”) and as of 5:00 p.m. New York time on October 31, 2014 became a stand-alone public company upon the completion of a spin-off from former Parent. 
Director Compensation
All Outside (non-employee) Directors receive annual compensation of $75,000 for the year for service as Directors.  For the initial organizational activities relating to the Spin, the Directors received a one-time addition to the annual retainer of $5,000.  The Chairperson of the Audit Committee of the Board of Directors and the Chairperson of the Compensation and Governance Committee of the Board of Directors each receive an additional $10,000 annual retainer fee. 
The Directors can elect to receive some or all of their annual retainer fees in shares of Common Stock under the Company’s 2014 Stock Option and Incentive Plan.  Directors are also reimbursed for travel expenses incurred in connection with Board and Committee meeting attendance.
An Outside Director is a director who is not an employee of the Company or one of its subsidiaries.  Donald D. Charron, Chairman of the Board and Chief Executive Officer, is a Director of the Company but does not receive compensation for his service as a Director.
Named Executive Officer Compensation
Base Pay
Periodically, the Compensation and Governance Committee of the Board of Directors reviews and approves the salaries that are paid to the Company’s executive officers.  The following are the current annualized base salaries for the Company’s Named Executive Officers:
	
				
	Donald D. Charron, Chairman of the Board, Chief Executive Officer
	$
	642,876
	

	John H. Kahle, Vice President, General Counsel and Secretary
	$
	397,800
	

	Steven T. Korn, Vice President, North American Operations
	$
	288,132
	

	Michael K. Sergesketter, Vice President, Chief Financial Officer
	$
	262,704
	

	Christopher J. Thyen, Vice President, Business Development
	$
	265,668
	

Cash Incentive Compensation
Each of the Named Executive Officers was eligible to participate in former Parent’s Profit Sharing Incentive Bonus Plan (the “former Parent’s Plan”) during fiscal year 2014.  Under the former Parent’s Plan, cash incentives are accrued annually and paid in five installments over the succeeding fiscal year.  Except for provisions relating to retirement, death, permanent disability, and certain other circumstances described in a participant’s employment agreement, participants must be actively employed on each payment date to be eligible to receive any unpaid cash incentive installment.  The total amount of cash incentives accrued and authorized to be paid to the Named Executive Officers based on former Parent’s fiscal year 2014 results is listed below.  The Named Executive Officers received an installment of 50% of the payment in August 2014, 12.5% was paid in each of September 2014, January 2015, and April 2015, and the remaining 12.5% will be paid in June 2015.
	
				
	Donald D. Charron, Chairman of the Board, Chief Executive Officer
	$
	548,912
	

	John H. Kahle, Vice President, General Counsel and Secretary
	$
	338,130
	

	Steven T. Korn, Vice President, North American Operations
	$
	247,034
	

	Michael K. Sergesketter, Vice President, Chief Financial Officer
	$
	220,909
	

	Christopher J. Thyen, Vice President, Business Development
	$
	219,204
	

Stock Compensation
The Named Executive Officers may also receive a variety of stock incentive benefits under the Company’s 2014 Stock Option and Incentive Plan consisting of: incentive stock options, stock appreciation rights, restricted shares, unrestricted shares, restricted share units, or performance shares and performance units.
During August 2013, the Named Executive Officers were awarded grants of performance shares under former Parent’s 2003 Amended and Restated Stock Option and Incentive Plan (the “former Parent’s 2003 Plan”).  Under the former Parent’s 2003 Plan, performance shares include both an annual performance share (“APS”) award and a long-term performance share (“LTPS”) award with one-fifth (1/5) of the LTPS award vesting annually over the succeeding five-year period.
The following table summarizes the performance shares issued in former Parent’s Common Stock during August 2014 to the Company’s Named Executive Officers pursuant to their August 2013 performance share awards, which were applicable to fiscal year 2014 performance under former Parent’s 2003 Plan:
	
						
	 
	FY 2014
APS Grant
(Shares Issued) (1)
	 
	FY 2014
LTPS Grant
(Shares Issued) (1)

	Donald D. Charron, Chairman of the Board, Chief Executive Officer
	6,825
	

	 
	30,700
	

	John H. Kahle, Vice President, General Counsel and Secretary
	6,375
	

	 
	31,300
	

	Steven T. Korn, Vice President, North American Operations
	3,185
	

	 
	5,900
	

	Michael K. Sergesketter, Vice President, Chief Financial Officer
	3,185
	

	 
	5,900
	

	Christopher J. Thyen, Vice President, Business Development
	3,185
	

	 
	5,900
	

	 
	 
	 
	 

	(1) Shares have not been reduced by the number of shares withheld to satisfy tax withholding obligations.

Pursuant to the Company’s 2014 Stock Option and Incentive Plan, performance shares include both an annual performance share (“APS”) award and a long-term performance share (“LTPS”) award with the award vesting annually over a specified period.
The following table summarizes the maximum number of performance shares granted in June 2014 and February 2015 to the Company’s Named Executive Officers for fiscal year 2015: 

	
									
	 
	APS Award
 (number of
 shares) (1)
	 
	APS Award
 (number of
 shares) (2)
	 
	LTPS Award
 (number of
 shares) (1)

	Donald D. Charron, Chairman of the Board, Chief Executive Officer
	10,282
	

	 
	—
	

	 
	32,980
	

	John H. Kahle, Vice President, General Counsel and Secretary
	10,282
	

	 
	—
	

	 
	32,980
	

	Steven T. Korn, Vice President, North American Operations
	4,850
	

	 
	5,563
	

	 
	6,596
	

	Michael K. Sergesketter, Vice President, Chief Financial Officer
	4,850
	

	 
	3,949
	

	 
	6,596
	

	Christopher J. Thyen, Vice President, Business Development
	4,850
	

	 
	4,237
	

	 
	6,596
	

	 
	 
	 
	 
	 
	 

	(1) Shares granted in June 2014 for the fiscal year 2015 performance period under former Parent’s 2003 Plan in former Parent’s stock.  On December 2, 2014, these outstanding awards were amended to provide an equitable adjustment and to be granted in the Company’s stock.  These shares have been increased due to the spin-off by an adjustment factor of 1.94 in accordance with the terms of the plans.

	(2) Additional shares granted in February 2015 for the fiscal year 2015 performance period under the Company’s 2014 Stock Option and Incentive Plan.  The purpose is to bring certain members of the Company’s management team and other key employees closer to their market value for total compensation and compensation mix as well as to recognize exceptional performance and contributions during the spin-off.

The number of shares to be issued will be dependent upon the percentage payout under the Company’s 2014 Stock Option and Incentive Plan.  The annual performance shares vest after the end of the Company’s fiscal year.  Refer to the Company’s registration statement on Form 10 for further details.
Retirement Plans
The Named Executive Officers participate in a defined contribution, participant-directed retirement plan that all domestic employees are eligible to participate in (the “Retirement Plan”).  The Retirement Plan provides for voluntary employee contributions as well as a discretionary Company contribution which is determined annually by the Compensation and Governance Committee of the Board of Directors.  Each eligible employee’s Company contribution is defined as a percent of eligible compensation, the percent being identical for all eligible employees, including Named Executive Officers.  Participant contributions are fully vested immediately, and Company contributions are fully vested after five years of participation.  All Named Executive Officers are fully vested.  The Retirement Plan is fully funded.  For those eligible employees who, under the 1986 Tax Reform Act, are deemed to be highly compensated, their individual Company contribution under the Retirement Plan is reduced.  For employees who are eligible, including all Named Executive Officers, there is a nonqualified, Supplemental Employee Retirement Plan (“SERP”) in which the Company contributes to the account of each individual an amount equal to the reduction in the contribution under the Retirement Plan arising from the provisions of the 1986 Tax Reform Act. The SERP investment is primarily composed of employee contributions.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00245-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00245-of-00352.parquet"}]]